Heterocyclic compounds as inhibitors of class I PI3KS

• US 9,637,488 B2
• Filed: 01/27/2016
• Issued: 05/02/2017
• Est. Priority Date: 01/29/2015
• Status: Active Grant

• Current Assignee: Ruan, Fuqiang
• Original Assignee: Ruan, Fuqiang
• Inventors: Ruan, Fuqiang
• Primary Examiner(s): Heyer, Dennis
• Application Number:
  US14/998,635
• Publication Number:
  US 20160222012A1
• Time in Patent Office: 461 Days
• Field of Search: None
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/506 not condensed and containing further heterocyclic rings
• CPC Class Codes: A61K 31/52 Purines, e.g. adenine
• CPC Class Codes: A61K 31/5377 not condensed and containing further heterocyclic rings, e.g. timolol
• CPC Class Codes: A61K 31/55 having seven-membered rings, e.g. azelastine, pentylenetetrazole
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: C07D 401/14 containing three or more hetero rings
• CPC Class Codes: C07D 473/34 attached in position 6, e.g. adenine

Abstract

The present application discloses a novel class of heterocycles as class I PI3Ks inhibitors. The compounds claimed herein could be used alone or in combination therapies for the treatment of a wide range of disorders such as autoimmune, inflammatory and allergic diseases, asthma, COPD, parasitic infections, diabetes, and cancer.

Claims

1. A compound having the structure of formula (I):

2. The compound or a pharmaceutically acceptable salt thereof according to claim 1, wherein R₂ and R₃ are independently selected from:

hydrogen, deuterium, —

F, —

Cl, or —

CH₃.

4. The compound of claims 1, 2 or 3, or a pharmaceutically acceptable salt thereof, wherein the compound is selected from:

3. A compound having the structure of formula (II):